Cargando…

Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

BACKGROUND: Single‐arm trials are currently an accepted study design to investigate the efficacy of novel therapies (NT) in non‐muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) immunotherapy as randomized controlled trials are either unfeasible (comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wettstein, Marian S., Naimark, David, Hermanns, Thomas, Herrera‐Caceres, Jaime O., Ahmad, Ardalan, Jewett, Michael A.S., Kulkarni, Girish S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221312/ https://www.ncbi.nlm.nih.gov/pubmed/32163677 http://dx.doi.org/10.1002/cam4.2980

Ejemplares similares

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy
por: Bhindi, Bimal, et al.
Publicado: (2016)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets
por: Claps, Francesco, et al.
Publicado: (2023)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients
por: Li, Roger, et al.
Publicado: (2017)

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
por: Lebacle, Cedric, et al.
Publicado: (2021)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
por: Benidir, Tarik, et al.
Publicado: (2021)

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
por: Sun, Kai, et al.
Publicado: (2021)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

What Recent Announcements Really Mean
Publicado: (1921)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
por: Wettstein, Marian S., et al.
Publicado: (2019)

Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
por: Broughton, Edward I., et al.
Publicado: (2022)

Meaningful futility: requests for resuscitation against medical recommendation
por: Vivas, Lucas, et al.
Publicado: (2021)

In silico analysis of similar protein sequences between Sars-Cov-2 and BCG vaccine
por: Tulgar, Busra Goksel, et al.
Publicado: (2021)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Transfer of specific unresponsiveness to organ allografts by thymocytes. Specific unresponsiveness by thymocyte transfer
Publicado: (1979)

Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2(+) T cells compared with the aminobisphosphonate drug zoledronic acid
por: Fenn, J, et al.
Publicado: (2022)

“Makes you proud to be black eh?”: Reflections on meaningful Indigenous research participation
por: Kelly, Jenny, et al.
Publicado: (2012)

Involving society in science: Reflections on meaningful and impactful stakeholder engagement in fundamental research
por: Garrison, Helen, et al.
Publicado: (2021)

Adherence to the WCRF/AICR Cancer Prevention Recommendations and Risk of Recurrence in Non-muscle Invasive Bladder Cancer
por: van Zutphen, Moniek, et al.
Publicado: (2022)

Vaccine-Induced Subcutaneous Granulomas in Goats Reflect Differences in Host–Mycobacterium Interactions between BCG- and Recombinant BCG-Derivative Vaccines
por: Liebler-Tenorio, Elisabeth M., et al.
Publicado: (2022)

Methylene blue unresponsive methemoglobinemia
por: Patnaik, Sibabratta, et al.
Publicado: (2014)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Methylene blue unresponsive methemoglobinemia
por: Mirakbari, Seyed Mostafa
Publicado: (2014)

An unresponsive COVID-19 patient
por: Nepal, Pankaj, et al.
Publicado: (2020)

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
por: Dómine Gómez, Manuel, et al.
Publicado: (2021)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study
por: Bieri, Uwe, et al.
Publicado: (2022)

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
por: Nguyen, Sylvain, et al.
Publicado: (2022)

Doing Internet research with hard-to-reach communities: methodological reflections on gaining meaningful access
por: Kaufmann, Mareile, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_64us1sip997t29gjl82bj61rof